These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 721057)

  • 41. Use of saralasin as a diagnostic test in hypertension. Report of a Consensus Committee.
    Arch Intern Med; 1982 Aug; 142(8):1437-40. PubMed ID: 7049102
    [No Abstract]   [Full Text] [Related]  

  • 42. The use of saralasin in the recognition of angiotensinogenic hypertension.
    Streeten DH; Dalakos TG; Anderson GH
    Prog Biochem Pharmacol; 1976; 12():214-26. PubMed ID: 1019165
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of 12-hour infusions of saralasin or captopril on blood pressure in hypertensive conscious rats. Relationship to plasma renin, duration of hypertension, and effect of unclipping.
    Bing RF; Russell GI; Swales JD; Thurston H
    J Lab Clin Med; 1981 Aug; 98(2):302-10. PubMed ID: 7019368
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Overview of the role of angiotensin inhibitors in delineating the function of the renin-angiotensin system.
    McCaa RE
    Prog Biochem Pharmacol; 1980; 17():29-35. PubMed ID: 7010367
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Differential diagnosis of hypertension using the angiotensin II antagonist saralasin].
    Knauf H; Burmeister P; Büttner C; Hoppe-Seyler G; Schollmeyer P
    Verh Dtsch Ges Kreislaufforsch; 1977; 43():214-5. PubMed ID: 613578
    [No Abstract]   [Full Text] [Related]  

  • 46. [Anti-hypertensive effect of the angiotensin II antagonist saralasin acetate, a diagnostic criterion of renovascular hypertension].
    Wessels F; Wagner H; Erhard R; Peters P; Losse H
    Med Welt; 1978 Mar; 29(9):339-41. PubMed ID: 634129
    [No Abstract]   [Full Text] [Related]  

  • 47. [Various inhbitors of the renin-angiotensin system and their clinical use].
    Bar-Andziak E
    Pol Arch Med Wewn; 1979 Jan; 61(1):69-74. PubMed ID: 370806
    [No Abstract]   [Full Text] [Related]  

  • 48. [Renal hypertension (author's transl)].
    Omae T
    Nihon Naika Gakkai Zasshi; 1978 Feb; 67(2):133-44. PubMed ID: 349100
    [No Abstract]   [Full Text] [Related]  

  • 49. [Effect of saralasin on blood pressure, plasma renin and plasma noradrenaline in hypertensive patients].
    Bönner G; Lang R; Hummerich W; Helber A; Meurer KA; Wambach G; Kaufmann W
    Med Welt; 1980 Sep; 31(38):1362, 1363-5. PubMed ID: 7001167
    [No Abstract]   [Full Text] [Related]  

  • 50. Depressor effect of saralasin in hypertensive crisis due to pheochromocytoma.
    Röckel A; Heidland A; Appel E; Palm D
    N Engl J Med; 1977 Jan; 296(1):50-1. PubMed ID: 830274
    [No Abstract]   [Full Text] [Related]  

  • 51. Lowering of hypertension by central saralasin in the absence of plasma renin.
    Phillips MI; Mann JF; Haebara H; Hoffman WE; Dietz R; Schelling P; Ganten D
    Nature; 1977 Dec; 270(5636):445-7. PubMed ID: 593364
    [No Abstract]   [Full Text] [Related]  

  • 52. A new look at the hypertension problem: the role of the renin system for analysis and treatment.
    Laragh JH
    Compr Ther; 1985 Oct; 11(10):6-17. PubMed ID: 3902342
    [No Abstract]   [Full Text] [Related]  

  • 53. Clinical evaluation of renovascular hypertension and therapeutic decisions.
    Vaughan ED; Case DB; Pickering TG; Sosa RE; Sos TA; Laragh JH
    Urol Clin North Am; 1984 Aug; 11(3):393-407. PubMed ID: 6205495
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Angiotensin antagonists as diagnostic and pharmacologic tools.
    Pettinger WA; Mitchell HC
    Prog Biochem Pharmacol; 1976; 12():203-13. PubMed ID: 798203
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Therapeutic prospects in the use of saralasin].
    Pigliucci GM; Valenza M; Rosati F; Cagossi M
    Chir Patol Sper; 1979 Oct; 27(5):491-7. PubMed ID: 261945
    [No Abstract]   [Full Text] [Related]  

  • 56. The effects of the angiotensin II antagonist saralasin on blood pressure and plasma aldosterone in man in relation to the prevailing plasma angiotensin II concentration.
    Brown JJ; Brown WC; Fraser R; Lever AF; Morton JJ; Robertson JI; Rosei EA; Trust PM
    Prog Biochem Pharmacol; 1976; 12():230-41. PubMed ID: 1019166
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Grand rounds: diagnosis and management of renovascular hypertension.
    Carey RM
    Va Med; 1979 Nov; 106(11):809-18. PubMed ID: 388907
    [No Abstract]   [Full Text] [Related]  

  • 58. Clinical pharmacology of angiotensin antagonists.
    Pettinger WA; Mitchell HC
    Fed Proc; 1976 Nov; 35(13):2521-5. PubMed ID: 976494
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Central hypertensive actions of angiotensin.
    Vollmer R; Buckley JP; Solomon TA; Jandhyala BS
    Acta Physiol Lat Am; 1974; 24(5):582-6. PubMed ID: 4377510
    [No Abstract]   [Full Text] [Related]  

  • 60. [Effect of hemorrhagic hypotension and inhibitory drugs of renin-angiotensin system upon endocrine and renal functions (author's transl)].
    Yamashita M
    Masui; 1977 Nov; 26(12):1482-93. PubMed ID: 599636
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.